GoodRx Cash Flow Statement
NASDAQ: GDRXTechnologyEDP ServicesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
GoodRx free cash flow
In fiscal 2025, GoodRx generated $167.9 million of operating cash flow and spent $3.5 million on capital expenditures. That left free cash flow of $164.4 million, a free-cash-flow margin of 20.6% of revenue. Free cash flow was down 10.0% from the prior year's $182.7 million.
GoodRx returned $216.4 million to shareholders through share repurchases, equal to 132% of free cash flow.
Summary generated from market data by MetaCap's automated system. Methodology
GoodRx cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Net Income | 30.44M | 16.39M | -8.87M | -32.83M | -25.25M | -293.62M | 66.05M | 43.79M |
| Net Income growth (YoY) | +85.72% | — | — | — | — | -544.56% | +50.82% | — |
| Depreciation & Amortization | 85.22M | 69.54M | 107.67M | 54.18M | 34.54M | 18.43M | 13.57M | 9.81M |
| Stock-Based Compensation | 76.63M | 99.03M | 104.82M | 120.23M | 160.46M | 397.29M | 3.75M | 1.76M |
| Change in Working Capital | -90.31M | -5.78M | -30.20M | -11.02M | -23.39M | -52.05M | -13.94M | -11.85M |
| Operating Cash Flow | 167.90M | 183.89M | 138.29M | 146.78M | 178.78M | 131.34M | 83.29M | 45.25M |
| Capital Expenditures | -3.52M | -1.24M | -1.04M | -3.97M | -4.57M | -20.55M | -1.43M | -804.00K |
| Investing Cash Flow | -119.96M | -70.35M | -55.77M | -210.50M | -178.73M | -91.62M | -37.05M | -3.46M |
| Dividends Paid | — | — | — | — | — | — | — | -1.35B |
| Share Repurchases | -216.37M | -158.84M | -103.97M | -101.72M | 0 | 0 | — | — |
| Debt Issued | 0 | 472.03M | 0 | 0 | 0 | 28.00M | 154.61M | 901.81M |
| Debt Repaid | -5.00M | -639.04M | -5.27M | -7.03M | -7.03M | -35.03M | -211.84M | -294.94M |
| Financing Cash Flow | -234.47M | -337.50M | -167.40M | -120.23M | -30.53M | 905.82M | -54.78M | -24.73M |
| Net Change in Cash | -186.53M | -223.95M | -84.87M | -183.94M | -30.48M | 945.54M | -8.55M | 17.06M |
| Free Cash Flow | 164.38M | 182.65M | 137.25M | 142.81M | 174.21M | 110.79M | 81.86M | 44.45M |
This table shows 8 annual periods of GoodRx's cash flow statement, from FY 2025 back to FY 2018, across 14 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow GDRX's reporting calendar. What is a cash flow statement?